logo
  

Hess Corporation Posts Loss In Q1 - Quick Facts

Hess Corporation (HES) reported a first-quarter net loss to company of $389 million or $1.37 per share, compared to net income of $386 million or $1.20 per share, prior year. Adjusted net loss, which excludes items affecting comparability, was $279 million or $0.98 per share, for the first quarter of 2015. The company said lower realized selling prices reduced adjusted net income by approximately $700 million, after-tax compared with the prior-year quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report a loss per share of $1.06 for the quarter. Analysts' estimates typically exclude special items.

Exploration and Production losses were $286 million in the first quarter of 2015, compared with net income of $508 million in the first quarter of 2014.

Total revenues and non-operating income decreased to $1.55 billion from $2.59 billion last year. Analysts expected revenue of $1.39 billion for the quarter.

"We delivered strong operating results for the quarter and captured significant cost savings for the year, with additional reductions being pursued," CEO John Hess said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT